Loading clinical trials...
Loading clinical trials...
A Phase II Pilot Study of yttriuM-90 in Combination With capEcitabine and aTezolizumab for oligomEtastatic cOlorectal Cancer With unResectable lIver MeTastasEs (METEORITE)
Conditions
Interventions
yttrium-90 radioembolization
Locations
1
United States
Lifespan Cancer Institute: The Miriam and Rhode Island Hospitals Providence, Rhode Island, United States, 02903 Contact:
Providence, Rhode Island, United States
Start Date
April 7, 2025
Primary Completion Date
September 1, 2026
Completion Date
September 1, 2029
Last Updated
April 9, 2025
NCT05059717
NCT05116696
Lead Sponsor
Brown University
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions